Subjects: LEUCEMIA, ANTINEOPLÁSICOS
ABNT
ASHAYE, Ajibade et al. Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial. Leukemia, v. 39, n. 6, p. 1342-1350, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/87063. Acesso em: 23 jan. 2026.APA
Ashaye, A., Shi, L., Aldoss, I., Montesinos, P., Vachhani, P., Rocha, V. G., et al. (2025). Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial. Leukemia, 39( 6), 1342-1350. doi:10.1038/s41375-025-02608-4NLM
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha VG, Papayannidis C, Leonard JT, Baer MR, Ribera J-M. Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial [Internet]. Leukemia. 2025 ; 39( 6): 1342-1350.[citado 2026 jan. 23 ] Available from: https://observatorio.fm.usp.br/handle/OPI/87063Vancouver
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha VG, Papayannidis C, Leonard JT, Baer MR, Ribera J-M. Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial [Internet]. Leukemia. 2025 ; 39( 6): 1342-1350.[citado 2026 jan. 23 ] Available from: https://observatorio.fm.usp.br/handle/OPI/87063
